Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 5/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.41 |
| ▸ | CCR1 | P32246 | 5/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | FPR3 | P25089 | 1/20 | 0.40 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3401374 | 0.88 | MGLL (0.47) | MGLLFAAHPTGDR2DRD2DRD4 | |
| SCHEMBL1632730 | 0.87 | MGLL (0.40) | MGLLFAAHPTGDR2CCR1CHRM4 | |
| SCHEMBL3395625 | 0.85 | CHRM3 (0.49) | MGLLCHRM3 | |
| SCHEMBL4048497 | 0.83 | CHRM2 (0.49) | MGLLPTGDR2CHRM4CHRM3DPP4 | |
| SCHEMBL4049044 | 0.80 | KCNH2 (0.48) | MGLLFAAHPTGDR2CHRM4CHRM3 | |
| SCHEMBL4208304 | 0.78 | CYP2E1 (0.42) | MGLLFAAHPTGDR2CCR1CHRM3 | |
| SCHEMBL4212875 | 0.78 | CHRM3 (0.55) | CHRM4CHRM3 | |
| SCHEMBL3399340 | 0.78 | MGLL (0.43) | MGLLFAAHPTGDR2DRD2DRD4 | |
| SCHEMBL3400992 | 0.76 | CHRM3 (0.50) | CHRM3 | |
| SCHEMBL2767018 | 0.76 | CCR1 (0.46) | MGLLPTGDR2CCR1CHRM4FPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253908-A1 | NOVEL M3 MUSCARINIC ACETYLCHOINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED | 2009-10-08 | — | — | US | disclosed |
| US-20090149447-A1 | Novel M3 Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-06-11 | — | — | US | disclosed |
| EP-1725236-A4 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2009-05-13 | — | — | EP | disclosed |
| EP-1725236-A1 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005087236-A1 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149447-A1 | Novel M3 Muscarinic Acetylcholine Receptor Antagonists | CHRM3, CHRM2, CHRNA3 | MGLL 2225/4885FAAH 1638/4885PTGDR2 456/4885 |
| US-20090253908-A1 | NOVEL M3 MUSCARINIC ACETYLCHOINE RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRNA3 | MGLL 1971/4885FAAH 1557/4885PTGDR2 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.